New analysis shows Soliqua® 100/33 lowered HbA1c by more than 2% in patients with screening levels greater than 9%

Pressrelease - No. 6/2017

New analysis shows Soliqua^® 100/33 lowered HbA_1c by more than 2% in patients with screening levels greater than 9%

• All subgroups treated with Soliqua^® 100/33 achieved a mean HbA_1c of
  less than 7% after 30 weeks

Copenhagen, June 10, 2017 - Zealand Pharma's ("Zealand") partner Sanofi announced today that Soliqua^® 100/33 (insulin glargine and lixisenatide injection) 100 units/ml and 33 mcg/ml  lowered mean blood sugar levels (HbA_1c) by 1.09-2.41% after 30 weeks in adults with type 2 diabetes previously treated with 15-40 units of basal insulin daily.

The abstract is entitled "iGlarLixi Reduces A_1c to a Greater Extent Than Basal Insulin Therapy Regardless of A_1c Levels at Screening" (Niemoeller E et al. Poster presentation 1079-P, American Diabetes Association (ADA) 77th Scientific Sessions, San Diego, CA, U.S., June 10). This new post-hoc analysis of data from the LixiLan-L Phase 3 study, which grouped participants according to HbA_1c level at screening, also showed that all subgroups achieved a mean HbA_1c of less than 7% during the study period.¹

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Soliqua^® 100/33 is an injectable prescription medicine that contains two diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type 2 diabetes when used in conjunction with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide. Soliqua^® 100/33, which is intended to be used in conjunction with diet and exercise, is marketed as Suliqua^® in the EU.

For further information, please contact:
Britt Meelby Jensen, CEO and President
Tel.: +45 51 67 61 28, e-mail: [email protected]

Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Adlyxin^® in the U.S. and as Lyxumia^® in the rest of the world. Lixisenatide has been developed in a combination with basal insulin glargine (Lantus^®) and is marketed as Soliqua^® 100/33 in the U.S. and has been approved as Suliqua^® in Europe and launched in the Netherlands.

Zealand's clinical pipeline includes: dasiglucagon* (ZP4207, single-dose rescue treatment) for acute, severe hypoglycemia (Phase 2); glepaglutide* (ZP1848) for short bowel syndrome (Phase 2); dasiglucagon* (ZP4207, multiple-dose version) intended for use in a dual-hormone artificial pancreas system to reduce the risk of hypoglycemia and better diabetes management (Phase 2) and other earlier-stage clinical and preclinical peptide therapeutics.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/02267735-d0eb-44a6-a4b0-3d0a98e3a455